BioMed Realty Trust Inc Form 10-Q August 02, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

Commission File Number: 1-32261 (BioMed Realty Trust, Inc.) 000-54089 (BioMed Realty, L.P.)

BIOMED REALTY TRUST, INC. BIOMED REALTY, L.P.

(Exact name of registrant as specified in its charter)

Maryland 20-1142292 (BioMed Realty Trust, Inc.) (State or other jurisdiction of incorporation or organization) 20-1320636 (BioMed Realty, L.P.) (I.R.S. Employer Identification No.)

17190 Bernardo Center Drive

San Diego, California 92128 (Address of Principal Executive Offices) (Zip Code)

(858) 485-9840

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

BioMed Realty Trust, Inc.

Yes x No o

BioMed Realty, L.P. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

BioMed Realty Trust, Inc.

Yes x No o
BioMed Realty, L.P.

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

BioMed Realty Trust, Inc.:

Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o

(Do not check if a smaller reporting

company)

BioMed Realty, L.P.:

Large accelerated filer o Accelerated filer o Non-accelerated filer x Smaller reporting company o

(Do not check if a smaller reporting

company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

BioMed Realty Trust, Inc.

Yes o No x

BioMed Realty, L.P. Yes o No x

The number of outstanding shares of BioMed Realty Trust, Inc.'s common stock, par value \$0.01 per share, as of August 2, 2012 was 154,186,244.

EXPLANATORY NOTE

This report combines the quarterly reports on Form 10-Q for the quarter ended June 30, 2012 of BioMed Realty Trust, Inc., a Maryland corporation, and BioMed Realty, L.P., a Maryland limited partnership of which BioMed Realty Trust, Inc. is the parent company and general partner. Unless otherwise indicated or unless the context requires otherwise, all references in this report to "we," "us," "our" or "our company" refer to BioMed Realty Trust, Inc. together with its consolidated subsidiaries, including BioMed Realty, L.P. Unless otherwise indicated or unless the context requires otherwise, all references in this report to "our operating partnership" or "the operating partnership" refer to BioMed Realty, L.P. together with its consolidated subsidiaries.

BioMed Realty Trust, Inc. operates as a real estate investment trust, or REIT, and the general partner of BioMed Realty, L.P. As of June 30, 2012, BioMed Realty Trust, Inc. owned an approximate 98.1% partnership interest and other limited partners, including some of our directors, executive officers and their affiliates, owned the remaining 1.9% partnership interest (including long term incentive plan units) in BioMed Realty, L.P. As the sole general partner of BioMed Realty, L.P., BioMed Realty Trust, Inc. has the full, exclusive and complete responsibility for the operating partnership's day-to-day management and control.

There are a few differences between our company and our operating partnership, which are reflected in the disclosure in this report. We believe it is important to understand the differences between our company and our operating partnership in the context of how BioMed Realty Trust, Inc. and BioMed Realty, L.P. operate as an interrelated consolidated company. BioMed Realty Trust, Inc. is a REIT, whose only material asset is its ownership of partnership interests of BioMed Realty, L.P. As a result, BioMed Realty Trust, Inc. does not conduct business itself, other than acting as the sole general partner of BioMed Realty, L.P., issuing public equity from time to time and guaranteeing certain debt of BioMed Realty, L.P. BioMed Realty Trust, Inc. itself does not hold any indebtedness but guarantees some of the secured and unsecured debt of BioMed Realty, L.P. BioMed Realty, L.P. holds substantially all the assets of the company and holds the ownership interests in the company's joint ventures. BioMed Realty, L.P. conducts the operations of the business and is structured as a partnership with no publicly traded equity. Except for net proceeds from public equity issuances by BioMed Realty, Trust, Inc., which are generally contributed to BioMed Realty, L.P. in exchange for partnership units, BioMed Realty, L.P. generates the capital required by the company's business through BioMed Realty, L.P.'s operations, by BioMed Realty, L.P.'s direct or indirect incurrence of indebtedness or through the issuance of partnership units.

Noncontrolling interests and stockholders' equity and partners' capital are the main areas of difference between the consolidated financial statements of BioMed Realty Trust, Inc. and those of BioMed Realty, L.P. The operating partnership and long term incentive plan units in BioMed Realty, L.P. that are not owned by BioMed Realty Trust, Inc. are accounted for as partners' capital in BioMed Realty, L.P.'s financial statements and as noncontrolling interests in BioMed Realty, L.P.'s financial statements include the interests of joint venture partners. The noncontrolling interests in BioMed Realty Trust, Inc.'s financial statements include the same noncontrolling interests at the BioMed Realty, L.P. level as well as the limited partnership unitholders of BioMed Realty, L.P., not including BioMed Realty Trust, Inc. The differences between stockholders' equity and partners' capital result from the differences in the equity issued at the BioMed Realty Trust, Inc. and the BioMed Realty, L.P. levels.

We believe combining the quarterly reports on Form 10-Q of BioMed Realty Trust, Inc. and BioMed Realty, L.P. into this single report:

better reflects how management and the analyst community view the business as a single operating unit,

enhances investor understanding of our company by enabling them to view the business as a whole and in the same manner as management,

is more efficient for our company and results in savings in time, effort and expense, and

is more efficient for investors by reducing duplicative disclosure and providing a single document for their review.

To help investors understand the significant differences between our company and our operating partnership, this report presents the following separate sections for each of BioMed Realty Trust, Inc. and BioMed Realty, L.P.:

consolidated financial statements,

the following notes to the consolidated financial statements:

Table of Contents

Equity / Partners' Capital,

Debt, and

Earnings Per Share / Unit,

Liquidity and Capital Resources in Management's Discussion and Analysis of Financial Condition and Results of Operations, and

Unregistered Sales of Equity Securities and Use of Proceeds.

This report also includes separate Item 4. Controls and Procedures sections and separate Exhibit 31 and 32 certifications for each of BioMed Realty Trust, Inc. and BioMed Realty, L.P. in order to establish that the Chief Executive Officer and the Chief Financial Officer of BioMed Realty Trust, Inc. have made the requisite certifications and BioMed Realty Trust, Inc. and BioMed Realty, L.P. are compliant with Rule 13a-15 or Rule 15d-15 of the Securities Exchange Act of 1934 and 18 U.S.C. §1350.

BIOMED REALTY TRUST, INC. AND BIOMED REALTY, L.P.

FORM 10-Q - QUARTERLY REPORT FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012 TABLE OF CONTENTS

	Page
PART I - FINANCIAL INFORMATION	
Item 1 Consolidated Financial Statements	
Consolidated Financial Statements of BioMed Realty Trust, Inc.:	
Consolidated Balance Sheets as of June 30, 2012 (Unaudited) and December 31, 2011	<u>6</u>
Consolidated Statements of Operations for the three and six months ended June 30, 2012 and 2011 (Unaudited)	7
Consolidated Statements of Comprehensive (Loss) / Income for the three and six months ended June 30, 2012 and 2011 (Unaudited)	<u>8</u>
Consolidated Statement of Equity for the six months ended June 30, 2012 (Unaudited)	9
Consolidated Statements of Cash Flows for the six months ended June 30, 2012 and 2011 (Unaudited)	<u>10</u>
Consolidated Financial Statements of BioMed Realty, L.P.:	
Consolidated Balance Sheets as of June 30, 2012 (Unaudited) and December 31, 2011	<u>12</u>
Consolidated Statements of Operations for the three and six months ended June 30, 2012 and 2011 (Unaudited)	<u>13</u>
Consolidated Statements of Comprehensive (Loss) / Income for the three and six months ended June 30, 2012 and 2011 (Unaudited)	<u>14</u>
Consolidated Statement of Capital for the six months ended June 30, 2012 (Unaudited)	<u>15</u>
Consolidated Statements of Cash Flows for the six months ended June 30, 2012 and 2011 (Unaudited)	<u>16</u>
Notes to Consolidated Financial Statements of BioMed Realty Trust, Inc. and BioMed Realty, L.P. (Unaudited)	<u>18</u>
Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>33</u>
Item 3 Quantitative and Qualitative Disclosures About Market Risk	<u>51</u>
Item 4 Controls and Procedures	<u>54</u>
PART II - OTHER INFORMATION	<u>55</u>
Item 1 Legal Proceedings	<u>55</u>

Item 1A Risk Factors	<u>55</u>
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds	<u>56</u>
Item 3 Defaults Upon Senior Securities	<u>56</u>
4	

<u>Item 4 Mine Safety Disclosures</u>	<u>56</u>
Item 5 Other Information	<u>57</u>
Item 6 Exhibits	<u>57</u>
<u>SIGNATURES</u>	<u>58</u>
Exhibit 31.1 Exhibit 31.2 Exhibit 32.1	
5	

PART I - FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BIOMED REALTY TRUST, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

	June 30, 2012 (Unaudited)	December 31, 2011	
ASSETS			
Investments in real estate, net	\$4,309,421	\$3,950,246	
Investments in unconsolidated partnerships	32,562	33,389	
Cash and cash equivalents	17,385	16,411	
Accounts receivable, net	4,241	5,141	
Accrued straight-line rents, net	139,346	130,582	
Deferred leasing costs, net	185,354	157,255	
Other assets	111,383	135,521	
Total assets	\$4,799,692	\$4,428,545	
LIABILITIES AND EQUITY			
Mortgage notes payable, net	\$550,704	\$587,844	
Exchangeable senior notes	180,000	180,000	
Unsecured senior notes, net	893,737	645,581	
Unsecured senior term loan	400,000	_	
Unsecured line of credit	78,000	268,000	
Accounts payable, accrued expenses and other liabilities	157,829	134,924	
Total liabilities	2,260,270	1,816,349	
Equity:			
Stockholders' equity:			
Preferred stock, \$.01 par value, 15,000,000 shares authorized: 7.375% Series A			
cumulative redeemable preferred stock, \$198,000,000 liquidation preference	191,469	191,469	
(\$25.00 per share), 7,920,000 shares issued and outstanding at June 30, 2012 and	171,407	171,407	
December 31, 2011			
Common stock, \$.01 par value, 200,000,000 shares authorized, 154,183,744 and			
154,101,482 shares issued and outstanding at June 30, 2012 and December 31,	1,542	1,541	
2011, respectively			
Additional paid-in capital	2,776,046	2,773,994	
Accumulated other comprehensive loss, net		(60,138)	
Dividends in excess of earnings		(304,759)	
Total stockholders' equity	2,530,626	2,602,107	
Noncontrolling interests	8,796	10,089	
Total equity	2,539,422	2,612,196	
Total liabilities and equity	\$4,799,692	\$4,428,545	

See accompanying notes to consolidated financial statements.

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share data)

(Unaudited)

	For the Three Months Ended			For the Six Months Ended			
	June 30,		June 30,				
	2012		2011	2012		2011	
Revenues:							
Rental	\$95,708		\$81,145	\$187,183		\$161,050	
Tenant recoveries	28,939		24,723	57,390		49,264	
Other revenue	201		541	285		1,288	
Total revenues	124,848		106,409	244,858		211,602	
Expenses:							
Rental operations	37,044		31,298	73,773		62,371	
Depreciation and amortization	47,575		35,696	92,508		69,447	
General and administrative	8,576		6,694	17,191		14,115	
Acquisition-related expenses	12,245		334	12,879		653	
Total expenses	105,440		74,022	196,351		146,586	
Income from operations	19,408		32,387	48,507		65,016	
Equity in net loss of unconsolidated partnerships	(317)	(466	(671)	(1,115)
Interest expense, net	(23,825)	(23,378	(46,044)	(44,568)
Other expense	(549)	(691	(375)	(1,745)
(Loss) / income from continuing operations	(5,283)	7,852	1,417		17,588	
Income / (loss) from discontinued operations	49		95	(4,370)	236	
Net (loss) / income	(5,234)	7,947	(2,953)	17,824	
Net loss / (income) attributable to noncontrolling	172		(68	201		(175	`
interests	1/2		(00	201		(173)
Net (loss) / income attributable to the Company	(5,062)	7,879	(2,752)	17,649	
Preferred stock dividends	(3,651)	(4,241	(7,301)	(8,481)
Net (loss) / income available to common stockholders	\$(8,713)	\$3,638	\$(10,053)	\$9,168	
(Loss) / income from continuing operations per share							
available to common stockholders:							
Basic and diluted earnings per share	\$(0.06)	\$0.03	\$(0.04)	\$0.07	
(Loss) / income from discontinued operations per share							
available to common stockholders:							
Basic and diluted earnings per share	\$		\$ —	\$(0.03)	\$ —	
Net (loss) / income per share available to common							
stockholders:							
Basic and diluted earnings per share	\$(0.06)	\$0.03	\$(0.07)	\$0.07	
Weighted-average common shares outstanding:							
Basic	152,775,422	2	129,858,098	152,715,715		129,815,154	
Diluted	152,775,422	2	132,840,932	152,715,715		132,803,097	

See accompanying notes to consolidated financial statements.

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) / INCOME (In thousands) (Unaudited)

	Three Months Ended			Six Months Ended				
	June 30,				June 30,			
	2012		2011		2012		2011	
Net (loss) / income	\$(5,234)	\$7,947		\$(2,953)	\$17,824	
Other comprehensive income:								
Foreign currency translation adjustments	2,991		_		2,991		_	
Unrealized (loss) / gain on derivative instruments, net	(3,372)	864		(3,597)	3,409	
Amortization of deferred interest costs	1,736		1,760		3,479		3,525	
Reclassification on unrealized loss on equity securities	545		825		545		825	
Reclassification on sale of equity securities	(60)	_		(32)	_	
Unrealized loss on equity securities	(254)	(1,375)	(519)	(3,692)
Total other comprehensive income	1,586		2,074		2,867		4,067	
Comprehensive (loss) / income	(3,648)	10,021		(86)	21,891	
Comprehensive loss / (income) attributable to noncontrolling interests	141		(114)	146		(265)
Comprehensive (loss) / income attributable to the Company	\$(3,507)	\$9,907		\$60		\$21,626	

See accompanying notes to consolidated financial statements.

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENT OF EQUITY

(In thousands, except share data) (Unaudited)

	Series A	Common Sto	ock	Additional	Accumula	ated. Dividends	Total	Nonconti	ralling
	Preferred Stock	Shares	Amoun	Capital	Comprehe Loss, net	in Excess ensive of Earnings	0. 11 11	Interests	rolling Total Equi
Balance at December 31, 2011	\$191,469	154,101,482	\$1,541	\$2,773,994			\$2,602,107	\$10,089	\$2,612,196
Net issuances of unvested restricted common stock	_	45,041	_	(3,401)	ı —	_	(3,401) —	(3,401
Conversion of OP units to common stock	_	37,221	1	30	_	_	31	(31)	
Vesting of share-based awards Reallocation of equit		_	_	5,576	_	_	5,576	_	5,576
to noncontrolling interests	<u> </u>	_	_	(153)	· —	_	(153) 153	_
Common stock dividends	_	_	_	_	_	(66,293)) (66,293) —	(66,293
OP unit distributions	_	_	_	_	_			(1,269)	(1,269
Net loss	_	_	_	_	_	(2,752)) (2,752		(2,953
Preferred stock dividends	_	_	_	_	_	(7,301)	(7,301) —	(7,301
Foreign currency translation adjustmen Reclassification on	nt	_	_	_	2,935	_	2,935	56	2,991
other-than-temporary impairment of marketable securities	_	_	_	_	535	_	535	10	545
Reclassification on sale of marketable securities	_	_	_	_	(32)	ı —	(32) —	(32
Unrealized loss on equity securities	_	_	_	_	(509)	· —	(509) (10)) (519
Amortization of deferred interest cost	s—	_	_	_	3,413	_	3,413	66	3,479
Unrealized loss on derivative instruments, net	_	_	_	_	(3,530)	ı —	(3,530) (67)	(3,597
Balance at June 30, 2012	\$191,469	154,183,744	\$1,542	\$2,776,046	\$(57,326)	\$(381,105)	\$2,530,626	\$8,796	\$2,539,422

See accompanying notes to consolidated financial statements.

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 $(In\ thousands)$

(Unaudited)

Operating activities: Net (loss) / income		Six Month June 30,	s Ended	
Net (loss) / income			2011	
Net (loss) / income	Operating activities:			
Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization \$92,600 \$9,625 \$ \$93 \$100		\$(2.953) \$17.824	
Depreciation and amortization		Ψ(2,733) ψ17,024	
Allowance for doubtful accounts 8.33 9.31 Non-cash revenue adjustments 6.349 5.145 Other non-cash adjustments 11.862 6.621 Compensation expense related to restricted common stock and LTIP units 5.575 3.656 Distributions representing a return on capital from unconsolidated partnerships 1.088 816 Changes in operating assets and liabilities: 1.004 2.715 Accounts receivable 6.038 524 Accounts payable, accrued expenses and other liabilities 2.243 6.638 524 Accounts payable, accrued expenses and other liabilities 2.243 6.434 9.8172 Investing activities 108,118 81,772 Investing activities 779,703 81,537 9.	· · · · · · · · · · · · · · · · · · ·	92 600	69 625	
Non-cash revenue adjustments 6,349 5,145 Other non-cash adjustments 11,862 6,621 Compensation expense related to restricted common stock and LTIP units 5,575 3,656 Distributions representing a return on capital from unconsolidated partnerships 1,088 816 Changes in operating assets and liabilities: 1,004 2,715 Accounds receivable 1,004 2,715 Accounts traight-line rents (6,587 (9,402) Deferred leasing costs (6,587 (9,402) Other assets 6,038 524 Accounts payable, accrued expenses and other liabilities 2,243 (6,434) Net cash provided by operating activities 108,118 81,772 Investing activities: 108,118 81,772 Investing activities (365,751) (38,981) Contributions to unconsolidated partnerships, net (1,350)— Proceads from the sale of equity securities 110 — Proceeds from the sale of equity securities 110 — Peposits to escrow	•	•	•	
Other non-cash adjustments 11,862 6,621 Compensation expense related to restricted common stock and LTIP units 5,575 3,656 Distributions representing a return on capital from unconsolidated partnerships 1,088 816 Changes in operating assets and liabilities: 3,004 2,715 Accounts receivable 1,004 2,715 Accounts grainly line rents (9,934) (10,249) Deferred leasing costs (6,587) (9,402) Other assets 6,038 524 Accounts payable, accrued expenses and other liabilities 2,243 (6,434) Net cash provided by operating activities 108,118 81,772 Investing activities: 108,118 81,772 Purchases of investments in real estate and related intangible assets (365,751) (38,981) Capital expenditures (79,703) (81,537) Capital expenditures (79,703) (81,537) Purchases of debt and equity securities (36,57)) (38,981) Purchases of debt and equity securities <td></td> <td></td> <td></td> <td></td>				
Compensation expense related to restricted common stock and LTIP units 1,088 816	·			
Distributions representing a return on capital from unconsolidated partnerships 1,088 816 Changes in operating assets and liabilities:	· · · · · · · · · · · · · · · · · · ·	•	·	
Changes in operating assets and liabilities: Accounts receivable 1,004 2,715 Accrued straight-line rents (9,934) (10,249) Deferred leasing costs (6,587) (9,402) Other assets (6,587) (9,402) Other assets (6,038 524) Accounts payable, accrued expenses and other liabilities 2,243 (6,434) Net cash provided by operating activities 108,118 81,772 Investing activities: Purchases of investments in real estate and related intangible assets (365,751) (38,981) Capital expenditures (79,703) (81,537) Capital expenditures (79,703) (81,537) Purchases of debt and equity securities (1,350) Purchases of debt and equity securities (1,350) Purchases of debt and equity securities (10,000) Proceeds from the sale of equity securities (10,000) Proceeds from the sale of equity securities (10,000) Proceeds from the sale of equity securities (450,952) (122,568) Prayment of deferred loan costs (5,022) (3,466) Unsecured line of credit proceeds (498,000 145,475) Unsecured				
Accounts receivable 1,004 2,715 Accrued straight-line rents (9,934) (10,249) Deferred leasing costs (6,587) (9,402) Other assets 6,038 524 Accounts payable, accrued expenses and other liabilities 2,243 (6,434) Net cash provided by operating activities 108,118 81,772 Investing activities: 8 81,772 Purchases of investments in real estate and related intangible assets (365,751) (38,981) Capital expenditures (79,703) (81,537) Contributions to unconsolidated partnerships, net (1,350)— Purchases of debt and equity securities (3,258) (2,050) Proceeds from the sale of equity securities 110 — Proceeds from the sale of equity securities (1,000)— Proceeds from the sale of equity securities (1,000)— Net cash used in investing activities (1,000)— Proceads from the sale of equity securities (450,952) (3,466 <td< td=""><td></td><td>1,000</td><td>010</td><td></td></td<>		1,000	010	
Accrued straight-line rents (9,934 0,10,249 0) Deferred leasing costs (6,587 0,9402 0) Other assets (6,587 0,9402 0) Other assets (6,038 524 0,038 524 0,038 0.038		1.004	2.715	
Deferred leasing costs			•)
Other assets 6,038 524 Accounts payable, accrued expenses and other liabilities 2,243 (6,434) Net cash provided by operating activities 108,118 81,772 Investing activities: 108,118 81,772 Purchases of investments in real estate and related intangible assets (365,751) (38,981) Capital expenditures (79,703) (81,537) Contributions to unconsolidated partnerships, net (1,350)— Purchases of debt and equity securities (3,258) (2,050) Proceeds from the sale of equity securities 110 — Proceeds from the sale of equity securities (1,000)— Proceeds from the sale of equity securities (1,000)— Net cash used in investing activities (1,000)— Net cash used in investing activities (5,022) (3,466) Financing activities (5,022) (3,466) Payment of deferred loan costs (5,022) (3,466) Unsecured line of credit proceeds (498,000	· · · · · · · · · · · · · · · · · · ·	* *		
Accounts payable, accrued expenses and other liabilities 2,243 (6,434) Net cash provided by operating activities 108,118 81,772 Investing activities: 81,772 Purchases of investments in real estate and related intangible assets (365,751) (38,981) Capital expenditures (79,703) (81,537) Contributions to unconsolidated partnerships, net (1,350 — Purchases of debt and equity securities (3,258) (2,050) Proceeds from the sale of equity securities 110 — Peposits to escrow for acquisitions (1,000) — Net cash used in investing activities (1,000) — Net cash used in investing activities (5,022) (3,466) Financing activities: (5,022) (3,466) Unsecured line of credit proceeds 498,000 145,475 Unsecured line of credit payments (688,000) (416,725) Principal payments on mortgage notes payable (36,557) (33,268)		* *		,
Net cash provided by operating activities Investing activities: Purchases of investments in real estate and related intangible assets Capital expenditures Contributions to unconsolidated partnerships, net Purchases of debt and equity securities Purchases of debt and equity securities Proceeds from the sale of equity securities 110 Deposits to escrow for acquisitions Net cash used in investing activities Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments Principal payments on mortgage notes payable Proceeds from unsecured senior notes Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders Dividends paid to common stockholders Net cash provided by financing activities Reffect of exchange rate changes on cash and cash equivalents Net cash equivalents at beginning of period 16,411 108,188 81,772 108,898 108,898 108,597 108,898 108,258 109,032 109,034 100,000)
Investing activities: Purchases of investments in real estate and related intangible assets Capital expenditures (79,703) (81,537) Contributions to unconsolidated partnerships, net (1,350)— Purchases of debt and equity securities (3,258) (2,050) Proceeds from the sale of equity securities 110 — Deposits to escrow for acquisitions Net cash used in investing activities Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments (688,000) (416,725) Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Dividends paid to common stockholders Net cash provided by financing activities 247,815 397,460 Dividends paid to preferred stockholders Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents Potation (1,300)— Net increase / (decrease) in cash and cash equivalents Proceads and cash equivalents at beginning of period Proceads and cash equivalents at beginning of period			•	,
Purchases of investments in real estate and related intangible assets Capital expenditures Contributions to unconsolidated partnerships, net (1,350)— Purchases of debt and equity securities Proceeds from the sale of equity securities Deposits to escrow for acquisitions Net cash used in investing activities Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments Principal payments on mortgage notes payable Proceeds from unsecured senior notes Proceeds from unsecured senior notes Dividends paid to common stockholders Dividends paid to preferred stockholders Net cash provided by financing activities Procease / (decrease) in cash and cash equivalents Possible (16,411 21,467 16,41	i i i i i i i i i i i i i i i i i i i	,	7	
Capital expenditures Contributions to unconsolidated partnerships, net Purchases of debt and equity securities Proceeds from the sale of equity securities 110 Deposits to escrow for acquisitions Net cash used in investing activities Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments Principal payments on mortgage notes payable Proceeds from unsecured senior notes Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders Dividends paid to preferred stockholders Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents Possess (16,411) (1,350 (1,350 (1,350 (1,000		(365,751) (38,981)
Contributions to unconsolidated partnerships, net Purchases of debt and equity securities Cig. 3,258 Proceeds from the sale of equity securities Proceeds from the sale of equity securities Cig. 3,258 Cig. 3,268 Cig. 3,268 Cig. 3,268 Cig. 3,268 Cig. 3,258 Cig. 3,268 Cig. 3,268 Cig. 3,258 Cig. 3,268 Cig. 3,26	-	•		
Purchases of debt and equity securities Proceeds from the sale of equity securities I10 Deposits to escrow for acquisitions Net cash used in investing activities Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders Dividends paid to common stockholders Dividends paid to preferred stockholders Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period 110	• •	•) —	,
Proceeds from the sale of equity securities Deposits to escrow for acquisitions Net cash used in investing activities Financing activities: Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders Dividends paid to common stockholders Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Cash and cash equivalents at beginning of period 110 — (1,000 (1,00) (2,050)
Deposits to escrow for acquisitions Net cash used in investing activities Rinancing activities: Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments Unsecured line of credit payments (688,000) (416,725) Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders Dividends paid to common stockholders Dividends paid to preferred stockholders Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period (1,000) — (450,952) (3,466) (5,022) (3,466) (488,000) (416,725) (485,725) (33,268) (400,000 — (400,0	_ ·		_	
Net cash used in investing activities Financing activities: Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments (688,000) (416,725) Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes 1400,000 — Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders (1,232) (1,107) Dividends paid to common stockholders (63,965) (48,526) Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 247,815 397,460 Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 243,738 31,362 Effect of exchange rate changes on cash and cash equivalents 70 — Net increase / (decrease) in cash and cash equivalents 974 (9,434) Cash and cash equivalents at beginning of period	_ · ·) —	
Financing activities: Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit payments Unsecured line of credit payments Unsecured line of credit payments (688,000) (416,725) Principal payments on mortgage notes payable (36,557) (33,268) Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders (1,232) (1,107) Dividends paid to common stockholders (63,965) (48,526) Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents (974 (9,434) Cash and cash equivalents at beginning of period) (122,568)
Payment of deferred loan costs Unsecured line of credit proceeds Unsecured line of credit proceeds Unsecured line of credit payments Unsecured line of credit payments Unsecured line of credit payments (688,000) (416,725) Principal payments on mortgage notes payable (36,557) (33,268) Proceeds from unsecured senior term loan Proceeds from unsecured senior notes 247,815 397,460 Distributions to operating partnership unit and LTIP unit holders (1,232) (1,107) Dividends paid to common stockholders (63,965) (48,526) Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 247,815 397,460 Dividends paid to common stockholders (7,301) (8,481) Net cash provided by financing activities 247,815 397,460 Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 247,815 397,460 Dividends paid to common stockholders (7,301) (8,481) Net cash provided by financing activities 247,815 397,460 Dividends paid to common stockholders (7,301) (8,481) Net cash provided by financing activities 247,815 397,460 Dividends paid to common stockholders (9,434) Cash and cash equivalents at beginning of period	-	, ,		
Unsecured line of credit proceeds Unsecured line of credit payments (688,000) (416,725) Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders Dividends paid to common stockholders Dividends paid to preferred stockholders Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period 498,000 145,475 (688,000) (416,725) (33,268) (400,000 — (1,232) (1,107) (48,526) (7,301) (8,481) (8,481) (9,434) Cash and cash equivalents at beginning of period	· · · · · · · · · · · · · · · · · · ·	(5,022) (3,466)
Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from unsecured senior term loan Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from		498,000	145,475	
Principal payments on mortgage notes payable Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from unsecured senior term loan Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from unsecured senior term loan Proceeds from unsecured senior notes Proceeds from	Unsecured line of credit payments	(688,000) (416,725)
Proceeds from unsecured senior notes Distributions to operating partnership unit and LTIP unit holders Dividends paid to common stockholders Dividends paid to preferred stockholders (63,965) (48,526) Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 343,738 31,362 Effect of exchange rate changes on cash and cash equivalents 70 — Net increase / (decrease) in cash and cash equivalents 974 (9,434) Cash and cash equivalents at beginning of period		(36,557) (33,268	
Distributions to operating partnership unit and LTIP unit holders (1,232) (1,107) Dividends paid to common stockholders (63,965) (48,526) Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 343,738 31,362 Effect of exchange rate changes on cash and cash equivalents 70 — Net increase / (decrease) in cash and cash equivalents 974 (9,434) Cash and cash equivalents at beginning of period	Proceeds from unsecured senior term loan	400,000		
Dividends paid to common stockholders Dividends paid to preferred stockholders Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period (63,965) (48,526) (7,301) (8,481) 343,738 31,362 70 — Net increase / (decrease) in cash and cash equivalents 974 (9,434) 16,411 21,467	Proceeds from unsecured senior notes	247,815	397,460	
Dividends paid to common stockholders (63,965) (48,526) Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 343,738 31,362 Effect of exchange rate changes on cash and cash equivalents 70 — Net increase / (decrease) in cash and cash equivalents 974 (9,434) Cash and cash equivalents at beginning of period 16,411 21,467	Distributions to operating partnership unit and LTIP unit holders	(1,232) (1,107)
Dividends paid to preferred stockholders (7,301) (8,481) Net cash provided by financing activities 343,738 31,362 Effect of exchange rate changes on cash and cash equivalents 70 — Net increase / (decrease) in cash and cash equivalents 974 (9,434) Cash and cash equivalents at beginning of period 16,411 21,467	Dividends paid to common stockholders	(63,965) (48,526	
Effect of exchange rate changes on cash and cash equivalents Net increase / (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period 70 — 974 (9,434) 21,467	Dividends paid to preferred stockholders	(7,301) (8,481	
Net increase / (decrease) in cash and cash equivalents 974 (9,434) Cash and cash equivalents at beginning of period 16,411 21,467	Net cash provided by financing activities	343,738	31,362	
Cash and cash equivalents at beginning of period 16,411 21,467	Effect of exchange rate changes on cash and cash equivalents	70		
Cash and cash equivalents at beginning of period 16,411 21,467	Net increase / (decrease) in cash and cash equivalents	974	(9,434)
Cash and cash equivalents at end of period \$17,385 \$12,033	Cash and cash equivalents at beginning of period	16,411	21,467	
	Cash and cash equivalents at end of period	\$17,385	\$12,033	

Table of Contents

	Six Months E June 30,	Ended
	2012	2011
Supplemental disclosure of cash flow information:		
Cash paid during the period for interest (net of amounts capitalized of \$4,450 and \$3,311, respectively)	\$34,289	\$35,927
Supplemental disclosure of non-cash investing and financing activities:		
Accrual for preferred stock dividends declared	\$3,651	\$4,241
Accrual for common stock dividends declared	33,149	26,252
Accrual for distributions declared for operating partnership unit and LTIP unit holders	633	596
Accrued additions to real estate and related intangible assets	30,104	24,891
Deposits applied for acquisitions	18,649	1,800

See accompanying notes to consolidated financial statements.

BIOMED REALTY, L.P.

CONSOLIDATED BALANCE SHEETS

(In thousands, except unit data)

	June 30, 2012 (Unaudited)	December 31, 2011	
ASSETS			
Investments in real estate, net	\$4,309,421	\$3,950,246	
Investments in unconsolidated partnerships	32,562	33,389	
Cash and cash equivalents	17,385	16,411	
Accounts receivable, net	4,241	5,141	
Accrued straight-line rents, net	139,346	130,582	
Deferred leasing costs, net	185,354	157,255	
Other assets	111,383	135,521	
Total assets	\$4,799,692	\$4,428,545	
LIABILITIES AND CAPITAL			
Mortgage notes payable, net	\$550,704	\$587,844	
Exchangeable senior notes	180,000	180,000	
Unsecured senior notes, net	893,737	645,581	
Unsecured senior term loan	400,000	_	
Unsecured line of credit	78,000	268,000	
Accounts payable, accrued expenses and other liabilities	157,829	134,924	
Total liabilities	2,260,270	1,816,349	
Capital:			
Partners' capital:			
Preferred units, 7.375% Series A cumulative redeemable preferred units,			
\$198,000,000 liquidation preference (\$25.00 per unit), 7,920,000 units issued and	191,469	191,469	
outstanding at June 30, 2012 and December 31, 2011			
Limited partners' capital, 2,942,758 and 2,979,979 units issued and outstanding at	9.049	10,332	
June 30, 2012 and December 31, 2011, respectively	9,049	10,332	
General partner's capital, 154,183,744 and 154,101,482 units issued and	2,394,884	2,469,233	
outstanding at June 30, 2012 and December 31, 2011, respectively	2,394,004	2,409,233	
Accumulated other comprehensive loss	(55,727)	(58,594)	
Total partners' capital	2,539,675	2,612,440	
Noncontrolling interests deficit	(253)	(244)	
Total capital	2,539,422	2,612,196	
Total liabilities and capital	\$4,799,692	\$4,428,545	

See accompanying notes to consolidated financial statements.

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except unit data)

(Unaudited)

			For the Six M June 30,	onths Ended
	2012	2011	2012	2011
Revenues:				
Rental	\$95,708	\$81,145	\$187,183	\$161,050
Tenant recoveries	28,939	24,723	57,390	49,264
Other revenue	201	541	285	1,288
Total revenues	124,848	106,409	244,858	211,602
Expenses:				
Rental operations	37,044	31,298	73,773	62,371
Depreciation and amortization	47,575	35,696	92,508	69,447
General and administrative	8,576	6,694	17,191	14,115
Acquisition-related expenses	12,245	334	12,879	653
Total expenses	105,440	74,022	196,351	146,586
Income from operations	19,408	32,387	48,507	65,016
Equity in net loss of unconsolidated partnerships	(317			